دورية
Targeted therapy with the mutant IDH2inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
| العنوان: | Targeted therapy with the mutant IDH2inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome |
|---|---|
| المؤلفون: | DiNardo, Courtney D., Venugopal, Sangeetha, Lachowiez, Curtis, Takahashi, Koichi, Loghavi, Sanam, Montalban-Bravo, Guillermo, Wang, Xuemei, Carraway, Hetty, Sekeres, Mikkael, Sukkur, Ameenah, Hammond, Danielle, Chien, Kelly, Maiti, Abhishek, Masarova, Lucia, Sasaki, Koji, Alvarado, Yesid, Kadia, Tapan, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop M., Patel, Bhumika, Dezern, Amy, Roboz, Gail, Garcia-Manero, Guillermo |
| المصدر: | Blood Advances; June 2023, Vol. 7 Issue: 11 p2378-2387, 10p |
| مستخلص: | •Enasidenib, a selective inhibitor of mutant IDH2enzyme, is an effective treatment option in patients with IDH2mutMDS.•Durable responses occurred with enasidenib after prior HMA therapy and in combination with azacitidine in treatment-naïve patients. |
| قاعدة البيانات: | Supplemental Index |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 24739529 24739537 |
|---|---|
| DOI: | 10.1182/bloodadvances.2022008378 |